本页面由Tiger Trade Technology Pte. Ltd.提供服务

Oncolytics Biotech Inc

0.4745
-0.0825-14.81%
成交量:166.07万
成交额:85.85万
市值:6,215.95万
市盈率:-1.48
高:0.5800
开:0.5702
低:0.4743
收:0.5570
52周最高:1.32
52周最低:0.4743
股本:1.31亿
流通股本:1.27亿
量比:1.63
换手率:1.31%
股息:- -
股息率:- -
每股收益(TTM):-0.3215
每股收益(LYR):-0.3000
净资产收益率:-10187.64%
总资产收益率:-211.24%
市净率:-10.08
市盈率(LYR):-1.58

数据加载中...

2026/04/01

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2026/04/01

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2026/04/01

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/03/31

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/03/20

重要事件披露

Form 8-K - Current report
2026/03/19

重要事件披露

Form 8-K - Current report
2026/03/02

重要事件披露

Form 8-K - Current report
2026/02/24

重要事件披露

Form 8-K - Current report
2026/02/04

重要事件披露

Form 8-K - Current report
2026/01/15

重要事件披露

Form 8-K - Current report
2026/01/15

重要事件披露

Form 8-K - Current report
2026/01/12

重要事件披露

Form 8-K - Current report
2026/01/09

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2025/12/06

SEC问询函

Form CORRESP - Correspondence
2025/08/28

SEC问询函

Form CORRESP - Correspondence
2025/03/07

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/06/04

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/12

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/03/03

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/03/03

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]